Literature DB >> 21241346

Continuous deep sedation at the end of life and the 'natural death' hypothesis.

Kasper Raus1, Sigrid Sterckx, Freddy Mortier.   

Abstract

Surveys in different countries (e.g. the UK, Belgium and The Netherlands) show a marked recent increase in the incidence of continuous deep sedation at the end of life (CDS). Several hypotheses can be formulated to explain the increasing performance of this practice. In this paper we focus on what we call the 'natural death' hypothesis, i.e. the hypothesis that acceptance of CDS has spread rapidly because death after CDS can be perceived as a 'natural' death by medical practitioners, patients' relatives and patients. We attempt to show that the label 'natural' cannot be unproblematically applied to the nature of this end-of-life practice. We argue that the labeling of death following CDS as 'natural' death is related to a complex set of mechanisms which facilitate the use of this practice. However, our criticism does not preclude the view that CDS may be clinically and ethically justified in many cases.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21241346     DOI: 10.1111/j.1467-8519.2010.01861.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  9 in total

1.  Pediatric palliative sedation therapy with propofol: recommendations based on experience in children with terminal cancer.

Authors:  Doralina L Anghelescu; Hunter Hamilton; Lane G Faughnan; Liza-Marie Johnson; Justin N Baker
Journal:  J Palliat Med       Date:  2012-06-25       Impact factor: 2.947

2.  Mandatory consultation for palliative sedation? Reflections on Koper et al.

Authors:  L Robijn; K Raus; L Deliens; S Sterckx; K Chambaere
Journal:  Support Care Cancer       Date:  2014-05-07       Impact factor: 3.603

3.  Morally-Relevant Similarities and Differences Between Assisted Dying Practices in Paradigm and Non-Paradigm Circumstances: Could They Inform Regulatory Decisions?

Authors:  Jeffrey Kirby
Journal:  J Bioeth Inq       Date:  2017-10-05       Impact factor: 1.352

4.  Considerations of physicians about the depth of palliative sedation at the end of life.

Authors:  Siebe J Swart; Agnes van der Heide; Lia van Zuylen; Roberto S G M Perez; Wouter W A Zuurmond; Paul J van der Maas; Johannes J M van Delden; Judith A C Rietjens
Journal:  CMAJ       Date:  2012-02-13       Impact factor: 8.262

5.  The perspectives of clinical staff and bereaved informal care-givers on the use of continuous sedation until death for cancer patients: The study protocol of the UNBIASED study.

Authors:  Jane Seymour; Judith Rietjens; Jayne Brown; Agnes van der Heide; Sigrid Sterckx; Luc Deliens
Journal:  BMC Palliat Care       Date:  2011-03-04       Impact factor: 3.234

6.  Using continuous sedation until death for cancer patients: a qualitative interview study of physicians' and nurses' practice in three European countries.

Authors:  Jane Seymour; Judith Rietjens; Sophie Bruinsma; Luc Deliens; Sigrid Sterckx; Freddy Mortier; Jayne Brown; Nigel Mathers; Agnes van der Heide
Journal:  Palliat Med       Date:  2014-07-25       Impact factor: 4.762

7.  Continuous deep sedation and homicide: an unsolved problem in law and professional morality.

Authors:  Govert den Hartogh
Journal:  Med Health Care Philos       Date:  2016-06

8.  Palliative sedation challenging the professional competency of health care providers and staff: a qualitative focus group and personal written narrative study.

Authors:  Danièle Leboul; Régis Aubry; Jean-Michel Peter; Victor Royer; Jean-François Richard; Frédéric Guirimand
Journal:  BMC Palliat Care       Date:  2017-04-11       Impact factor: 3.234

9.  Continuous sedation until death: the everyday moral reasoning of physicians, nurses and family caregivers in the UK, The Netherlands and Belgium.

Authors:  Kasper Raus; Jayne Brown; Clive Seale; Judith A C Rietjens; Rien Janssens; Sophie Bruinsma; Freddy Mortier; Sheila Payne; Sigrid Sterckx
Journal:  BMC Med Ethics       Date:  2014-02-20       Impact factor: 2.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.